BEDFORD, Mass. - Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company, has received confirmation from the U.S. Food and Drug Administration (FDA) that its Phase 3 SOL-R clinical trial for AXPAXLI™, a treatment for wet age-related macular degeneration (wet AMD (NASDAQ:AMD)), is suitable as a second adequate and well-controlled study. This trial, along with the ongoing SOL-1 study, is intended to support a New Drug Application (NDA) for AXPAXLI™, assuming successful outcomes.
The FDA's Type C written response validates the SOL-R study as a non-inferiority trial for repeat dosing of AXPAXLI™. The SOL-1 study, in contrast, is a superiority trial evaluating a single implant of AXPAXLI™. Both trials are part of Ocular's strategy to align with FDA guidance and provide meaningful data for commercial use.
Enrollment for the SOL-1 study has accelerated, and those not meeting randomization criteria for SOL-1 are given the chance to enroll in SOL-R. The SOL-R study has quickly moved from concept to patient enrollment in less than three months, demonstrating Ocular's efficient clinical operations.
AXPAXLI™, also known as OTX-TKI, is a bioresorbable, hydrogel implant containing axitinib, a tyrosine kinase inhibitor with anti-angiogenic properties, currently being evaluated for the treatment of wet AMD and other retinal diseases. Wet AMD is a leading cause of severe vision loss, affecting millions globally, and is characterized by abnormal blood vessel growth in the retina.
The SOL-1 trial compares AXPAXLI™ to aflibercept injections, while the SOL-R trial compares AXPAXLI™ dosed every six months to aflibercept dosed every eight weeks. An additional arm in the SOL-R trial has been included for adequate masking, as recommended by the FDA.
Ocular Therapeutix is set to discuss recent business progress and financial results in a conference call and webcast today at 8:00 AM ET. The company's pipeline also includes DEXTENZA®, an FDA-approved corticosteroid for post-surgical ocular inflammation and pain, and PAXTRAVA™, a product candidate for glaucoma treatment.
This news article is based on a press release statement from Ocular Therapeutix, Inc.
In other recent news, Ocular Therapeutix reported Q1 2024 revenues of $14.8 million, marking a 10.5% year-over-year increase, despite a net loss of $64.8 million due to one-time expenses. The company also announced a workforce reduction to concentrate resources on the clinical development of Axpaxli.
Piper Sandler maintained an Overweight rating and a $15.00 price target for Ocular Therapeutix, focusing on the latest developments in the company's ongoing clinical trials.
TD Cowen upgraded Ocular Therapeutix from a Hold to a Buy rating, increasing the price target to $11 based on advancements in the company's clinical programs.
H.C. Wainwright reiterated its Buy rating for the company, adjusting its price target to $14. These are among the recent developments at Ocular Therapeutix.
InvestingPro Insights
Ocular Therapeutix, Inc. (NASDAQ:OCUL) continues to make strides in the biopharmaceutical industry with its promising clinical trials for AXPAXLI™. As the company prepares for the potential commercialization of its treatments, it's essential for investors to consider various financial metrics and analyst insights. According to InvestingPro data, Ocular Therapeutix has a market capitalization of approximately $1.22 billion, indicative of its significant presence in the biotech sector.
The company's commitment to research and development may be reflected in its negative gross profit margin of -21.04% for the last twelve months as of Q1 2024, which highlights the current costs exceeding revenues in this critical investment phase. This is a crucial period for Ocular as it advances its clinical trials, potentially leading to future profitability despite the present financial metrics suggesting otherwise. Furthermore, with a P/E ratio of -11.82, investors are valuing the company's growth prospects rather than current earnings.
InvestingPro Tips suggest that Ocular Therapeutix holds more cash than debt on its balance sheet, which could provide financial flexibility and stability as it pursues FDA approval for AXPAXLI™. Additionally, the company has seen a strong return over the last year, with a price total return of 80.96%, reflecting investor optimism in its long-term potential. However, analysts have revised their earnings downwards for the upcoming period, and do not anticipate the company will be profitable this year, which is a consideration for those assessing the company's near-term financial outlook.
For a more comprehensive analysis, investors can find 11 additional InvestingPro Tips on Ocular Therapeutix at https://www.investing.com/pro/OCUL, offering deeper insights into the company's financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.